13993-58-3

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloro-3,5-diiodopyridine is used as an intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical industry, 4-Chloro-3,5-diiodopyridine is used as a building block for the creation of new agrochemicals, contributing to the development of more effective and targeted pest control solutions.
Used in Dye Industry:
4-Chloro-3,5-diiodopyridine is utilized in the production of dyes, where its chemical properties enable the creation of vibrant and stable colorants for various applications.
Used in Organic Compounds and Materials Production:
4-Chloro-3,5-diiodopyridine is also used in the production of other organic compounds and materials, showcasing its versatility in different chemical processes and applications.

Upstream product

• 5579-93-1 3,5-diiodo-1H-pyridin-4-one 
• 7153-08-4 4-hydroxy-3,5-diiodopyridine 
• 626-64-2 pyridin-4-ol 
• 108-96-3 4-pyridone 

Downstream Products

• 63905-96-4 3,5-diiodo-pyridine-4-thiol 
• 377743-28-7 3,5-diiodo-4-(phenylthio)pyridine 
• 871875-87-5 3,5-diiodo-pyridine-4-sulfonic acid 
• 7153-08-4 4-hydroxy-3,5-diiodopyridine 
• 767333-76-6 4-ethoxy-3,5-diiodopyridine 
• 119-80-2 2,2'-dithiobenzoic acid 

Relevant academic research and scientific papers

Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19

The Mediator complex-associated cyclin-dependent kinase CDK8 has been implicated in human disease, particularly in colorectal cancer where it has been reported as a putative oncogene. Here we report the discovery of 109 (CCT251921), a potent, selective, and orally bioavailable inhibitor of CDK8 with equipotent affinity for CDK19. We describe a structure-based design approach leading to the discovery of a 3,4,5-trisubstituted-2-aminopyridine series and present the application of physicochemical property analyses to successfully reduce in vivo metabolic clearance, minimize transporter-mediated biliary elimination while maintaining acceptable aqueous solubility. Compound 109 affords the optimal compromise of in vitro biochemical, pharmacokinetic, and physicochemical properties and is suitable for progression to animal models of cancer.

PYRIDYL PIPERIDINES

The invention provides novel substituted pyridyl piperidine compounds according to Formula (I) which are Wnt pathway inhibitors, their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.

Quinoline derivatives as tyrosine kinase inhibitors

The invention concerns quinoline derivatives of formula (I) wherein n is 0-3 and each R4, which may be the same or different, is a substituent such as halogeno, hydroxy, amino, nitro, trifluoromethyl, trifluoromethoxy, cyano or (1-6C)alkyl, or

Simple zwitterionic merocyanines as potential NLO chromophores

A suite of zwitterionic pyridylidene-based merocyanines that contain no interconnecting π-bridge between the donor and acceptor rings has been synthesised and their second-order NLO properties evaluated largely by semi-empirical computational methods (MOP